Response to "Survival advantage for Etoposide/Cisplatin over Paclitaxel/Carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: A subgroup analysis for ECOG 2 patients would be of great interest"
Annals of oncology : official journal of the European Society for Medical Oncology, 2017.
Chemoradiotherapyconcomitantinoperablelocally-advanced NSCLCperformance status
Full Text (Upload PDF)
PPT (Upload PPT)